David Hollander

Insider Reports History

Location
Durham, NC
Signature
/s/ Melissa Tosca, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by David Hollander:

Company Role Class Num Shares Value Price $ Report Date Ownership
AERIE PHARMACEUTICALS INC Chief R&D Officer Common Stock 30,749 $468,922 $15.25 04 Feb 2022 Direct
Revance Therapeutics, Inc. CMO & Global Therapeutics Lead Common Stock 0 $0 $3.65 06 Feb 2025 Direct
KIORA PHARMACEUTICALS INC Director Stock Option (right to buy) 20,000 01 Apr 2025 Direct

Insider Reports Filed by David Hollander

Symbol Company Period Transactions Value $ Form Type Role Filing Time
KPRX KIORA PHARMACEUTICALS INC 01 Apr 2025 1 $0 4 Director 02 Apr 2025, 20:15
RVNC Revance Therapeutics, Inc. 04 Feb 2025 2 -$35,525 4 CMO & Global Therapeutics Lead 06 Feb 2025, 15:58
RVNC Revance Therapeutics, Inc. 18 Nov 2024 1 -$16,296 4 CMO & Global Therapeutics Lead 19 Nov 2024, 16:31
KPRX KIORA PHARMACEUTICALS INC 01 Jul 2024 1 $0 4 Director 03 Jul 2024, 15:15
RVNC Revance Therapeutics, Inc. 27 Feb 2024 0 $0 3 CMO & Global Therapeutics Lead 29 Feb 2024, 16:32
KPRX KIORA PHARMACEUTICALS INC 29 Sep 2023 1 $0 4 Director 03 Oct 2023, 16:44
KPRX KIORA PHARMACEUTICALS INC 03 Mar 2023 1 $0 4 Director 07 Mar 2023, 19:13
AERI AERIE PHARMACEUTICALS INC 04 Feb 2022 1 -$6,535 4 Chief R&D Officer 08 Feb 2022, 19:40
KPRX KIORA PHARMACEUTICALS INC 01 Feb 2022 2 $0 4 Director 03 Feb 2022, 18:02
KPRX KIORA PHARMACEUTICALS INC 13 Dec 2021 0 $0 3 Director 23 Dec 2021, 15:30
AERI AERIE PHARMACEUTICALS INC 11 Nov 2021 1 -$26,074 4 Chief R&D Officer 15 Nov 2021, 15:44